Jay Mazelsky joins Insulet (NASDAQ: PODD) board as independent director
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Insulet Corporation appointed Jonathan J. (Jay) Mazelsky as a Class II member of its Board of Directors, effective July 1, 2026. He will stand for election at the Company’s 2027 annual stockholder meeting and will serve as an independent director.
Mazelsky is Executive Chair of IDEXX Laboratories’ board and previously served there as President and CEO, with prior leadership roles at Philips Healthcare, Agilent Technologies, and Hewlett Packard. As a non-employee director, he will receive an initial grant of restricted stock units with a grant date fair value of $216,548, representing a pro-rated $260,000 annual equity award, plus cash compensation under Insulet’s non-employee director compensation program. The Company states there are no related-party arrangements or transactions requiring disclosure under Item 404(a) of Regulation S-K.
Positive
- None.
Negative
- None.
8-K Event Classification
3 items: 5.02, 7.01, 9.01
3 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Director effective date: July 1, 2026
Initial RSU grant value: $216,548
Annual equity award (pro-rated): $260,000
+2 more
5 metrics
Director effective date
July 1, 2026
Effective date of Jonathan J. Mazelsky’s appointment as Class II director
Initial RSU grant value
$216,548
Grant date fair value of initial restricted stock unit award to Mazelsky
Annual equity award (pro-rated)
$260,000
Target annual non-employee director equity award underlying the pro-rated RSU grant
Press release date
June 25, 2026
Date of Insulet’s press release announcing Mazelsky’s appointment
Board class
Class II director
Board classification for Mazelsky’s seat, standing for election in 2027
Key Terms
Class II director, independent director, restricted stock units, non-employee director compensation program, +2 more
6 terms
Class II director financial
"appointed Jonathan J. Mazelsky as a Class II director, effective July 1, 2026"
A class II director is a member of a company’s board who belongs to one of several staggered groups of directors, each group standing for election in different years. For investors, this matters because staggered terms slow wholesale board turnover—like rotating members of a neighborhood committee—making sudden changes in control or strategy harder and affecting how quickly shareholders can influence corporate direction.
independent director financial
"Mr. Mazelsky joins the Board as an independent director"
An independent director is a member of a company's board of directors who is not involved in the company's day-to-day operations and has no significant relationships with the company that could influence their judgment. Their role is to provide unbiased oversight and ensure the company is managed in the best interests of all shareholders. This helps build trust and confidence among investors by promoting transparency and accountability.
restricted stock units financial
"will receive an initial grant of restricted stock units with a grant date fair value of $216,548"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
non-employee director compensation program financial
"cash compensation pursuant to the Company's non-employee director compensation program"
Item 404(a) of Regulation S-K regulatory
"There are no transactions involving Mr. Mazelsky required to be disclosed under Item 404(a) of Regulation S-K"
Automated Insulin Delivery System technical
"Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System"
An automated insulin delivery system is a device that automatically monitors blood sugar levels and adjusts insulin delivery without needing manual input. Think of it as a smart thermostat that keeps a room’s temperature just right, ensuring stable levels. For investors, such systems represent advances in healthcare technology that can improve quality of life and potentially reduce long-term medical costs.
